

Teva launches Qvar Redihaler inhalation aerosol in US market

14 February 2018 | News

QVAR RediHaler differs from conventional metered-dose inhalers, as it delivers medication via a breath-actuated inhaler



Teva Pharmaceutical's QVAR RediHaler (beclomethasone dipropionate HFA) Inhalation Aerosol is now commercially available in the market.

In the US QVAR RediHaler is the first and only breath-actuated aerosol inhaled corticosteroid.

It is used for the treatment of asthma as a prophylactic therapy in patients 4 years of age and older. It is not indicated for the relief of acute bronchospasm.

QVAR RediHaler differs from conventional metered-dose inhalers (MDIs) as it delivers medication via a breath-actuated inhaler, eliminating the need for hand-breath coordination during inhalation.

QVAR RediHaler administers the same active ingredient found in the previously available QVAR (beclomethasone dipropionate HFA) Inhalation Aerosol, but utilizes innovative breath-actuated inhaler technology.

QVAR RediHaler was also designed to be ready for use, with no shaking or priming needed. Because the medication delivery is breath actuated, it should not be used with a spacer or volume holding chamber.